|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 221.38 USD | +0.03% |
|
-.--% | +0.22% |
| 01-09 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2000 Value Benchmark | CI |
| 01-09 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2500 Value Benchmark | CI |
| Market Cap | 6.96B 6.12B 5.69B 5.23B 9.82B 667B 9.95B 67.69B 26.44B 330B 26.12B 25.56B 1,139B | P/E 2023 |
-3.03x | P/E 2024 | -1.01x |
|---|---|---|---|---|---|
| Enterprise Value | 6.77B 5.95B 5.54B 5.09B 9.56B 649B 9.68B 65.88B 25.73B 321B 25.42B 24.88B 1,108B | EV / Sales 2023 |
0.64x | EV / Sales 2024 | 84.5x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
Last Transcript: Cidara Therapeutics
| 1 day | +0.03% | ||
| Current year | +0.22% |
| Current year | 220.47 |  | 221.42 |
| 1 year | 56.53 | | 221.42 |
| 3 years | 10 | | 221.42 |
| 5 years | 8 | | 221.42 |
| 10 years | 8 | | 259 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Karbe
DFI | Director of Finance/CFO | 58 | 24/02/2025 |
Corrina Pavetto
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2025 |
| Chief Tech/Sci/R&D Officer | - | 01/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 7/1/26 | Issuer sale | Chief Operating Officer | 241,829 | 0.9537% | ||
| 7/1/26 | Issuer sale | Director | 41,100 | 0.1621% | ||
| 7/1/26 | Issuer sale | Director | 42,920 | 0.1693% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 63.9M 56.18M 52.3M 48.03M 90.18M 6.13B 91.37M 622M 243M 3.03B 240M 235M 10.46B | 1.28M 1.12M 1.04M 958K 1.8M 122M 1.82M 12.4M 4.84M 60.38M 4.79M 4.68M 209M |
| Net income | -22.93M -20.16M -18.77M -17.23M -32.36M -2.2B -32.79M -223M -87.11M -1.09B -86.08M -84.23M -3.75B | -170M -149M -139M -128M -240M -16.29B -243M -1.65B -645M -8.04B -638M -624M -27.8B |
| Net Debt | -30.9M -27.17M -25.29M -23.22M -43.61M -2.96B -44.18M -301M -117M -1.46B -116M -113M -5.06B | -186M -164M -152M -140M -263M -17.86B -266M -1.81B -708M -8.82B -699M -684M -30.48B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CDTX Stock
Select your edition
All financial news and data tailored to specific country editions
